Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

Key Points

• To evaluate the effect of corticosteroid premedication on toxicity and survival rates in patients treated with enfortumab vedotin for urothelial carcinoma.
• Conducted an observational study of patients receiving enfortumab vedotin.
• Analyzed the correlation between corticosteroid premedication and reported skin toxicities.
• Monitored survival outcomes in relation to premedication use.
• Corticosteroid premedication significantly reduced skin toxicities during treatment.
• Survival impact of corticosteroid premedication remains uncertain and needs further validation.

Abstract